1 – 10 of 15
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction—Outcomes at two years
(
- Contribution to journal › Article
- 2023
-
Mark
Prognostic Value of Early Sustained Ventricular Arrhythmias in ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention : A Substudy of VALIDATE-SWEDEHEART Trial
(
- Contribution to journal › Article
-
Mark
European practice patterns for antiplatelet management in NSTE-ACS patients : Results from the REal-world ADoption survey focus on Acute antiPlatelet Treatment (READAPT) survey
(
- Contribution to journal › Article
- 2022
-
Mark
Trends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery
(
- Contribution to journal › Article
- 2021
-
Mark
Outcome of PCI with Xience versus other commonly used modern drug eluting stents : A SCAAR report
(
- Contribution to journal › Article
-
Mark
Uninterrupted Oral Anticoagulant Therapy in Patients Undergoing Unplanned Percutaneous Coronary Intervention
(
- Contribution to journal › Article
- 2020
-
Mark
Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction : a VALIDATE-SWEDEHEART substudy
(
- Contribution to journal › Article
- 2019
-
Mark
Mechanical chest compressions for cardiac arrest in the cath-lab : When is it enough and who should go to extracorporeal cardio pulmonary resuscitation?
(
- Contribution to journal › Article
- 2018
-
Mark
Coronary angiographic findings and outcomes in patients with sudden cardiac arrest without ST-elevation myocardial infarction : A SWEDEHEART study
(
- Contribution to journal › Article
- 2017
-
Mark
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction
(
- Contribution to journal › Article